TRDA Q4 2023 Earnings — Entrada Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TRDAEntrada Therapeutics, Inc.

$502M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M

Gross Profit

$42M100.0% margin

Operating Income

$5M11.7% margin

Net Income

-$10M-22.8% margin

EPS (Diluted)

$-0.29

QoQ Revenue Growth

-4.3%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$469M

Total Liabilities

$227M

Stockholders' Equity

$242M

Cash & Equivalents

$68M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$0	—
Gross Profit	$42M	$0	—
Operating Income	$5M	-$26M	+119.2%
Net Income	-$10M	-$25M	+61.2%